Poolbeg to present at Master Investor Show, BioTrinity & Participate in a Panel Discussion at LSX World Congress
27 March 2025 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs, announces that CEO, Jeremy Skillington, will be participating in the following leading industry conferences in March and April 2025:
Master Investor Show – Business Design Centre, London, UK
Presentation details: 29 March, Showcase Stage (Ground Floor), 1.00pm – 1.10pm
Poolbeg Pharma will be located at Booth M30.
BioTrinity – Convene, 133 Houndsditch, London, UK
Presentation details: 2 April, Science Spotlight 8 – Rare Disease, 9.30am – 11am
Poolbeg Pharma’s presentation will focus on its drug candidate POLB 001, an oral preventative therapy for cancer immunotherapy-induced CRS.
LSX World Congress – Business Design Centre, London, UK
Panel title: “Thriving Amidst Turbulence: Building Resilience in Life Sciences”
Panel date & time: 30 April, 2pm
If you would like to meet the Poolbeg team at any of the above events, please contact us at ir@poolbegpharma.com.
Enquiries
|
Poolbeg Pharma Plc Jeremy Skillington, CEO Ian O’Connell, CFO |
+44 (0) 207 183 1499 |
About Poolbeg Pharma plc
Poolbeg Pharma plc is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. Poolbeg comprises a strong and growing portfolio of development assets.
For more information, please go to www.poolbegpharma.com or follow us on Twitter and LinkedIn @PoolbegPharma.
